Traynor Capital Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Traynor Capital Management Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,720 shares of the biopharmaceutical company’s stock after buying an additional 3,107 shares during the quarter. Traynor Capital Management Inc.’s holdings in Pfizer were worth $625,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC increased its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock traded down $0.03 during midday trading on Friday, hitting $27.75. The company’s stock had a trading volume of 40,466,657 shares, compared to its average volume of 47,662,984. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $157.14 billion, a price-to-earnings ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a 50 day moving average of $27.46 and a two-hundred day moving average of $29.46.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the company posted $1.14 EPS. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Barclays reduced their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, UBS Group cut their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.